<DOC>
	<DOCNO>NCT01339897</DOCNO>
	<brief_summary>This Phase 1 study evaluate multiple dose across range find effective mouse model asthma safe one Phase 1 clinical trial . It intend provide evidence tolerability multiple dose well provide information Pharmacokinetic ( PK ) metabolism N6022 human .</brief_summary>
	<brief_title>A Safety Study Evaluating N6022 Multiple-Ascending Doses Healthy Subjects</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , multiple ascend dose study , least three ascend cohort . Twenty-four subject enrol initially first three cohort , 40 subject enrol overall additional cohort require reach maximum tolerate dose ( MTD ) . The cohort enrol two group 4 approximately 7 day group conduct safety monitoring committee review approval proceed second group cohort . Eight subject enrol per cohort , randomize 3:1 N6022 : placebo . Each subject undergo screening ( Day -28 Day -2 ) , eligible , instructed begin low-nitrate diet Day -4 . Subjects return clinical site Day -1 , eligibility reconfirm . Eligible subject receive dose investigational medicinal product ( [ IMP ] , N6022 placebo ) intravenous ( IV ) infusion study Days 1 7 follow safety , PK , PD discharge morning Day 8 . Subjects return clinic follow-up visit Day 15 ( ± 1 day ) contact via telephone Day 28 ( ± 1 day ) end-of-study safety follow-up visit . Participation individual subject may last approximately 56 day time screen end-of-study follow-up visit . A Safety Monitoring Committee ( SMC ) review safety data cohort Day 15 Follow-up visit , proceed next ascend dose cohort , modify dose , repeat dose , stop study accord stop rule outline protocol .</detailed_description>
	<criteria>1 . Subject healthy , determine prestudy medical evaluation ( medical history , physical examination , vital sign , 12lead ECG , clinical laboratory evaluation 2 . Subject nonsmoker ( nicotine user ) determine history ( nicotine use past year ) negative urine cotinine test screen Day 1 . 3 . Subject body weight &gt; 50 kg BMI 19.5 29.5 kg/m2 , inclusive , screen . 4 . Subject systolic BP &gt; 90 mmHg diastolic BP &gt; 50 mmHg screen Day1 . 1 . Subject clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) determine investigator designee . 2 . Subject current alcohol abuser and/or history illicit drug abuse within six month entry . 3 . Subject donate blood ( &gt; 500 mL ) blood product within 56 day prior Day 1 . 4 . Subject history bleeding disorder ( i.e. , severe hemorrhage , melena , rectal bleeding , nosebleed , bruising , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>N6022 , GSNORi</keyword>
</DOC>